chartexchange

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

GlobeNewswire Inc. | Nov 4, 2026 4:05 PM EST

Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027

Read original article